a Department of Process Engineering , Stellenbosch University , Stellenbosch , South Africa and.
Crit Rev Biotechnol. 2015;35(3):369-91. doi: 10.3109/07388551.2014.888048.
The production of raw starch-degrading amylases by recombinant Saccharomyces cerevisiae provides opportunities for the direct hydrolysis and fermentation of raw starch to ethanol without cooking or exogenous enzyme addition. Such a consolidated bioprocess (CBP) for raw starch fermentation will substantially reduce costs associated with energy usage and commercial granular starch hydrolyzing (GSH) enzymes. The core purpose of this review is to provide comprehensive insight into the physiological impact of recombinant amylase production on the ethanol-producing yeast. Key production parameters, based on outcomes from modifications to the yeast genome and levels of amylase production, were compared to key benchmark data. In turn, these outcomes are of significance from a process point of view to highlight shortcomings in the current state of the art of raw starch fermentation yeast compared to a set of industrial standards. Therefore, this study provides an integrated critical assessment of physiology, genetics and process aspects of recombinant raw starch fermenting yeast in relation to presently used technology. Various approaches to strain development were compared on a common basis of quantitative performance measures, including the extent of hydrolysis, fermentation-hydrolysis yield and productivity. Key findings showed that levels of α-amylase required for raw starch hydrolysis far exceeded enzyme levels for soluble starch hydrolysis, pointing to a pre-requisite for excess α-amylase compared to glucoamylase for efficient raw starch hydrolysis. However, the physiological limitations of amylase production by yeast, requiring high biomass concentrations and long cultivation periods for sufficient enzyme accumulation under anaerobic conditions, remained a substantial challenge. Accordingly, the fermentation performance of the recombinant S. cerevisiae strains reviewed in this study could not match the performance of conventional starch fermentation processes, based either on starch cooking and/or exogenous amylase enzyme addition. As an alternative strategy, the addition of exogenous GSH enzymes during early stages of raw starch fermentation may prove to be a viable approach for industrial application of recombinant S. cerevisiae, with the process still benefitting from amylase production by CBP yeast during later stages of cultivation.
重组酿酒酵母生产生淀粉降解淀粉酶为直接水解和发酵生淀粉生产乙醇提供了机会,无需蒸煮或添加外源酶。这种用于生淀粉发酵的整合生物加工(CBP)将大大降低与能源使用和商业颗粒淀粉水解(GSH)酶相关的成本。本文的核心目的是全面了解重组淀粉酶生产对产乙醇酵母的生理影响。基于对酵母基因组的修饰和淀粉酶产量的结果,比较了关键生产参数,与关键基准数据进行了比较。反过来,从工艺角度来看,这些结果具有重要意义,突出了与一组工业标准相比,目前生淀粉发酵酵母的现状在工艺上的不足之处。因此,本研究从生理学、遗传学和工艺方面对重组生淀粉发酵酵母进行了综合的批判性评估,以与目前使用的技术相关。在定量性能衡量标准的基础上,对各种菌株开发方法进行了比较,包括水解程度、发酵-水解产率和生产力。主要发现表明,用于生淀粉水解的α-淀粉酶水平远远超过用于可溶性淀粉水解的酶水平,这表明与葡糖淀粉酶相比,高效生淀粉水解需要过量的α-淀粉酶。然而,酵母生产淀粉酶的生理限制仍然是一个重大挑战,需要高生物量浓度和在厌氧条件下长时间培养才能积累足够的酶。因此,根据淀粉蒸煮和/或外源淀粉酶酶添加,本研究中综述的重组酿酒酵母菌株的发酵性能无法与传统淀粉发酵工艺的性能相匹配。作为替代策略,在生淀粉发酵的早期阶段添加外源 GSH 酶可能被证明是工业应用重组酿酒酵母的可行方法,该工艺在培养后期仍受益于 CBP 酵母的淀粉酶生产。